Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker ENVB
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 3, 2026 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Sio Capital Management, LLC | 330,000 | 7.4% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Steven Boyd | 405,092 | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Armistice Capital, LLC | 405,092 | 10.0% | SCHEDULE 13G ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Jeff Easton | 51,866 | 1.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Lind Global Partners III LLC | 49,366 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Lind Global Fund III LP | 49,366 | 1.3% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Waqas Khatri | 111,145 | 2.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 111,145 | 2.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Ayrton Capital LLC | 111,145 | 2.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Jeff Easton | 161,232 | 7.9% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Lind Global Partners III LLC | 158,732 | 7.8% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Lind Global Fund III LP | 158,732 | 7.8% | SCHEDULE 13G/A ↗ |
| Feb 4, 2026 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Jeff Easton | 141,265 | 10.0% | SCHEDULE 13G ↗ |
| Feb 4, 2026 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Lind Global Partners III LLC | 141,265 | 10.0% | SCHEDULE 13G ↗ |
| Feb 4, 2026 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Lind Global Fund III LP | 141,265 | 10.0% | SCHEDULE 13G ↗ |
| Feb 2, 2026 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Intracoastal Capital LLC | 71,246 | 5.0% | SCHEDULE 13G ↗ |
| Feb 2, 2026 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Daniel B. Asher | 71,246 | 5.0% | SCHEDULE 13G ↗ |
| Feb 2, 2026 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Mitchell P. Kopin | 71,246 | 5.0% | SCHEDULE 13G ↗ |
| Jan 5, 2026 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | AdvisorShares Trust | 16,974 | 1.7% | SCHEDULE 13G/A ↗ |
| Dec 17, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Intracoastal Capital, LLC | 31,353 | 5.0% | SCHEDULE 13G ↗ |
| Dec 17, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Daniel B. Asher | 31,353 | 5.0% | SCHEDULE 13G ↗ |
| Dec 17, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Mitchell P. Kopin | 31,353 | 5.0% | SCHEDULE 13G ↗ |
| Dec 10, 2025 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Northstrive Fund II LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Dec 10, 2025 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Braeden Lichti | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Dec 10, 2025 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Braeden Lichti | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Dec 10, 2025 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Northstrive Fund II LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Dec 5, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Northstrive Fund II LP | 25,915 | 4.3% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Braeden Lichti | 29,920 | 5.0% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Braeden Lichti | 29,920 | 5.0% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Northstrive Fund II LP | 25,915 | 4.3% | SCHEDULE 13G ↗ |
| Nov 13, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Waqas Khatri | 658,465 | 10.0% | SCHEDULE 13G ↗ |
| Nov 13, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 658,465 | 10.0% | SCHEDULE 13G ↗ |
| Nov 13, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Ayrton Capital LLC | 658,465 | 10.0% | SCHEDULE 13G ↗ |
| Oct 3, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | AdvisorShares Trust | 203,679 | 6.3% | SCHEDULE 13G ↗ |
| Sep 24, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Intracoastal Capital LLC | 19,333 | 0.4% | SCHEDULE 13G ↗ |
| Sep 24, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Daniel B. Asher | 19,333 | 0.4% | SCHEDULE 13G ↗ |
| Sep 24, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Mitchell P. Kopin | 19,333 | 0.4% | SCHEDULE 13G ↗ |
| Apr 2, 2025 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | AdvisorShares Trust | 90,324 | 3.6% | SCHEDULE 13G/A ↗ |
| Feb 5, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Intracoastal Capital LLC | 103,951 | 5.0% | SCHEDULE 13G ↗ |
| Feb 5, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Daniel B. Asher | 103,951 | 5.0% | SCHEDULE 13G ↗ |
| Feb 5, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Mitchell P. Kopin | 103,951 | 5.0% | SCHEDULE 13G ↗ |
| Feb 4, 2025 | SCHEDULE 13G/A (amended) | ENVB Enveric Biosciences, Inc. | Orca Capital AG | 97,019 | 4.9% | SCHEDULE 13G/A ↗ |
| Feb 4, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | Orca Capital AG | 166,667 | 8.7% | SCHEDULE 13G ↗ |
| Jan 6, 2025 | SCHEDULE 13G | ENVB Enveric Biosciences, Inc. | AdvisorShares Trust | 599,854 | 5.9% | SCHEDULE 13G ↗ |
44 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 16, 2026, 6:54 AM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances